Drug Trial Radar · NCT06974565
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 12, 2025
Primary completion
Jul 18, 2025
Study completion Jul 18, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
Conditions
- Advanced Chronic Liver Disease
- Healthy Participants
Interventions
AZD2389Drug
AZD2389 will be administered orally.
QuinidineDrug
Quinidine will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on maximum observed plasma concentration (RCmax)Time frame: Day 1 to Day 10
- Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on area under concentration-time curve from time 0 to infinity (RAUCinf)Time frame: Day 1 to Day 10
- Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on area under concentration-time curve from time 0 to the last quantifiable concentration (RAUClast)Time frame: Day 1 to Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Brooklyn, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.